Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study



    Interim Results Show Promise for Improving the Treatment of Blockages in
    the Femoropopliteal Artery

    VANCOUVER, June 11 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced that its corporate partner, Cook Medical, has reported positive
interim results from the registry arm of a clinical study measuring the
effectiveness of its Zilver PTX drug-eluting peripheral stent in treating
peripheral arterial disease (PAD). The results, which were reported by the
trial investigators last week at the 2008 SVS Vascular Annual Meeting,
revealed clinical improvement, excellent durability and fracture resistance,
and high rates of event-free survival (EFS) and freedom from target lesion
revascularization (TLR). In addition, the Zilver stent exhibited no safety
concerns and results were better than expected for TASC class C and D lesions,
occlusions, in-stent restenosis and lesions greater than seven centimetres
(2.75 inches).
    "Building on the success of our paclitaxel-eluting coronary stents, we
are extremely pleased that Cook has met with early success in leveraging our
technology with this first round of positive trial data for the Zilver PTX
paclitaxel-eluting peripheral stent," said Dr. William Hunter, President and
CEO of Angiotech. "We are hopeful that Cook will encounter similarly positive
results throughout the duration of the Zilver PTX trial and we are excited
about the potential benefits the Zilver PTX stent may provide patients
suffering from PAD."
    Interim data was compiled at six and 12 months using 435 patients and 200
patients, respectively. The corresponding EFS rates were 94 percent and
84 percent, and freedom from TLR was 96 percent and 88 percent. Clinical
measures that included ankle-brachial index, Rutherford score, and walking
distance and speed scores showed significant improvement at six months that
was maintained through 12 months. Evaluation of stent x-rays is ongoing, and
currently suggests stent fractures in approximately one percent of cases at
six months and less than two percent of cases at 12 months. Follow-up to the
registry arm of the study will continue through two years.
    Under the terms of its 1997 License Agreement with Cook, Angiotech is
entitled to receive royalty payments upon the commercial sale of
paclitaxel-eluting peripheral vascular stent products, including the Zilver
PTX.
    The Zilver PTX is currently undergoing multiple clinical trials in the
United States, Asia, Latin America, Canada and Europe to assess product safety
and efficacy.

    Forward Looking Statements
    --------------------------
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; adverse results or unexpected delays
in drug discovery and clinical development processes; decisions, and the
timing of decisions, made by health regulatory agencies regarding approval of
our technology and products; the requirement for substantial funding to
conduct research and development, to expand commercialization activities or
consummate acquisitions or to service or repay debt obligations; the accuracy
of our estimations of the size of the market, and the potential market, for
our products in specific disease areas; sales numbers and future guidance
publicly provided by Boston Scientific Corporation regarding sales of their
paclitaxel-eluting coronary stent products; and any other factors that may
affect performance. In addition, our business is subject to certain operating
risks that may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from our actual
results. These operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete preclinical and
clinical development of our products; changes in business strategy or
development plans; our failure to obtain patent protection for discoveries;
loss of patent protection resulting from third party challenges to our
patents; commercialization limitations imposed by patents owned or controlled
by third parties; our ability to obtain rights to technology from licensors;
liability for patent claims and other claims asserted against us; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to maintain,
corporate alliances relating to the development and commercialization of our
technology and products; market acceptance of our technology and products; our
ability to successfully manufacture, market and sell our products; the ability
of Boston Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued availability
of capital to finance our activities; our ability to achieve the financial
benefits expected as a result of the acquisition of American Medical
Instruments Holdings, Inc.; and any other factors referenced in our annual
information form and other filings with the applicable Canadian securities
regulatory authorities or the Securities and Exchange Commission. Given these
uncertainties, assumptions and risk factors, readers are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained in this press
release to reflect future results, events or developments.

    Zilver(R) PTX(TM) are trademarks of Cook Medical.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: Deirdre Neary, Manager, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056,
dneary@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890